A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
Clinical trial NCT01911221 · COMPLETED
Trial details
- NCT number
- NCT01911221
- Sponsor
- Novartis Vaccines
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-01
- Primary completion
- 2014-04-01
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.